Popular terms

[SEARCH]

Sleep Disorders topics
Sleep Disorder
Sleep Disorders
Narcolepsy
Schizophrenia
Antagonist
Pyrazole Derivatives
Movement Disorder
Movement Disorders
Eating Disorder
Eating Disorders
Neurological
Pharmaceutically Acceptable Salt
Intracranial
Opiate Withdrawal
Growth Hormone

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Sleep Disorders patents



      
           
This page is updated frequently with new Sleep Disorders-related patent applications. Subscribe to the Sleep Disorders RSS feed to automatically get the update: related Sleep RSS feeds. RSS updates for this page: Sleep Disorders RSS RSS



Date/App# patent app List of recent Sleep Disorders-related patents
07/16/15
20150196257 
 Systems and methods for physiological signal enhancement and biometric extraction using non-invasive optical sensors patent thumbnailSystems and methods for physiological signal enhancement and biometric extraction using non-invasive optical sensors
A system and method for signal processing to remove unwanted noise components including: (i) wavelength-independent motion artifacts such as tissue, bone and skin effects, and (ii) wavelength-dependent motion artifact/noise components such as venous blood pulsation and movement due to various sources including muscle pump, respiratory pump and physical perturbation. Disclosed are methods, analytics, and their uses for reliable perfusion monitoring, arterial oxygen saturation monitoring, heart rate monitoring during daily activities and in hospital settings and for extraction of physiological parameters such as respiration information, hemodynamic parameters, venous capacity, and fluid responsiveness.
The Board Of Regents, The University Of Texas System


06/25/15
20150175573 
 Heteroaromatic compounds and their use as dopamine d1 ligands patent thumbnailHeteroaromatic compounds and their use as dopamine d1 ligands
And pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating d1-mediated (or d1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, ad, pd, or pharmacotherapy therapy), adhd, impulsivity, compulsive gambling, overeating, autism spectrum disorder, mci, age-related cognitive decline, dementia, rls, parkinson's disease, huntington's chorea, anxiety, depression, mdd, trd, bipolar disorder, chronic apathy, anhedonia, chronic fatigue, post-traumatic stress disorder, seasonal affective disorder, social anxiety disorder, post-partum depression, serotonin syndrome, substance abuse and drug dependence, drug abuse relapse, tourette's syndrome, tardive dyskinesia, drowsiness, excessive daytime sleepiness, cachexia, inattention, sexual dysfunction, migraine, sle, hyperglycemia, atherosclerosis, dislipidemia, obesity, diabetes, sepsis, post-ischemic tubular necrosis, renal failure, hyponatremia, resistant edema, narcolepsy, hypertension, congestive heart failure, postoperative ocular hypotonia, sleep disorders, and pain.. .

06/18/15
20150164945 
 Preparation for improving the action of receptors patent thumbnailPreparation for improving the action of receptors
This preparation is advantageously applied in patients suffering from parkinson's disease, huntington's chorea, epilepsy, schizophrenia, paranoia, depression, sleep disorders, impaired memory function, psychoses, dementia and adhd.. .

05/21/15
20150141669 
 Prodrug of fluorine-containing amino acid patent thumbnailProdrug of fluorine-containing amino acid
Provided are a fluorine-containing amino acid prodrug represented by general formula (i) that makes a fluorine-containing amino acid which is a group 2 metabotropic glutamate receptor agonist into a prodrug, or a pharmaceutically acceptable salt thereof. More specifically, provided is a prodrug that increases the in vivo exposure and enhances the oral absorbability and other mucosal absorbability of a parent compound that acts on group 2 metabotropic glutamate receptors as an agent for the treatment or prevention of diseases in which group 2 metabotropic glutamate receptors are said to be involved, such as: schizophrenia, anxiety disorder and its related diseases, depression, bipolar disorder, epilepsy, developmental disorders, sleep disorders, and other neuropsychiatric diseases; and drug dependence, cognitive disorders, alzheimer's disease, huntington's chorea, parkinson's disease, movement disorders associated with muscular rigidity, cerebral ischemia, cerebral insufficiency, spinal cord disorders, cephalopathy, and other neurological diseases..
Taisho Pharmaceutical Co., Ltd.


05/21/15
20150141444 
 N-methyl tetrahydroquinoline m1 receptor positive allosteric modulators patent thumbnailN-methyl tetrahydroquinoline m1 receptor positive allosteric modulators
The present invention is directed to n-methyl tetrahydroquinoline compounds of formula (i) which are m1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the m1 receptor is involved, such as alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the m1 receptor..
Merck Sharp & Dohme Corp.


05/14/15
20150133675 
 Pde10 inhibitors and related compositions and methods patent thumbnailPde10 inhibitors and related compositions and methods
Compounds that inhibit pde10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as parkinson's disease, huntington's disease, alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, bell's palsy, cerebral palsy, sleep disorders, pain, tourette's syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. Pharmaceutically acceptable salts, stereoisomers, solvates and prodrugs of the compounds are also provided.

05/14/15
20150132283 
 Botulinum toxin and the treatment of primary disorders of mood and affect patent thumbnailBotulinum toxin and the treatment of primary disorders of mood and affect
The invention provides methods for treating primary disorders of mood and affect, including depressive disorders, anxiety and sleep disorders and cns disorders comprising the administration of a neurotoxin.. .

05/07/15
20150125548 
 Combination nutritional and nutraceutical products patent thumbnailCombination nutritional and nutraceutical products
The present invention is directed to nutritional and nutraceutical compositions which comprise novel mixtures of two or more indole-based dietary supplements such as l-tryptophan and melatonin, together with selected minerals and vitamins that stimulate tryptophan metabolism in the direction of serotonin and melatonin, and to their use in a preferred embodiment of the invention in a readily ingested beverage form, optionally combined with a range of other natural ingredients designed to improve the health and state of mind of human subjects. Alternative dosage forms, such as tablets for oral dosing, and dosage forms for buccal and sublingual administration, including thin films, are also incorporated in the present invention.
Requis Pharmaceuticals Inc.


04/30/15
20150119381 
 Use of ghrelin receptor inverse agonists or antagonists for treating sleep disorders patent thumbnailUse of ghrelin receptor inverse agonists or antagonists for treating sleep disorders
The present invention relates to methods of treating sleep disorders in patients comprising administration of a ghrelin receptor inverse agonist or antagonist. The invention also includes methods of treating sleep disorders comprising the administration of a pharmaceutical composition comprising a ghrelin receptor inverse agonist or antagonist and at least one pharmaceutically acceptable carrier, diluent, or excipient..
Pfizer Inc.


04/09/15
20150099761 
 Modulators of fatty acid amide hydrolase patent thumbnailModulators of fatty acid amide hydrolase
4-(2,2-difluoro-benzo[1,3]dioxol-5-ylmethyl)-piperazine-1-carboxylic acid (4-chloro-pyridin-3-yl)-amide is described, which is useful as a faah modulator. 4-(2,2-difluoro-benzo[1,3]dioxol-5-ylmethyl)-piperazine-1-carboxylic acid (4-chloro-pyridin-3-yl)-amide may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (faah) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy metabolism disorders, and movement disorders (e.g., multiple sclerosis).
Janssen Pharmaceutica Nv


03/26/15
20150087894 

Method and device for monitoring and treating sleep disorders and sleep-related conditions


Methods and apparatus for monitoring, diagnosing, and treating sleep disorders such as sleep terrors are provided, which may include any number of features. One feature is an apparatus configured to partially awaken a user to treat a sleep disorder.

03/12/15
20150073052 

Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy


Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gamma-hydroxybutyrate that are also resistant to the conversion into gbl.
Jazz Pharmaceuticals, Inc.


03/05/15
20150065498 

N-linked lactam m1 receptor positive allosteric modulators


The present invention is directed to n-linked lactam compounds of general formula (i) which are m1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the m1 receptor is involved, such as alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the m1 receptor..

02/26/15
20150057443 

Cycloalkyl amine compounds


Wherein ring a is c3-c6 cycloalkyl, optionally substituted with one or more c1-c3 alkyl, and r5 is ors2, in which rs2 is h or c1-c6 alkyl, or r5 and r6, together with the carbon atom to which they are attached, form c═o, for use in treating cns disorders, including movement disorders, depressive disorders, sleep disorders, cognitive dysfunctions, obesity, sexual dysfunction and substance abuse.. .

02/19/15
20150051239 

Arylsulfonyl pyrazoline carboxamidine derivatives as 5-ht6 antagonists


This invention concerns arylsulfonyl pyrazoline carboxamidine derivatives as antagonists of 5-ht6 receptors, to methods for the preparation of these compounds and to novel intermediates useful for their synthesis. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in parkinson's disease, huntington's chorea, schizophrenia, anxiety, depression, manic depression, psychoses, epilepsy, obsessive compulsive disorders, mood disorders, migraine, alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, binge eating disorders, panic attacks, akathisia, attention deficit hyperactivity disorder, attention deficit disorder, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, disorders associated with spinal trauma or head injury, hydrocephalus, functional bowel disorder, irritable bowel syndrome, obesity and type-2 diabetes.
Abbvie Bahamas Limited


02/05/15
20150037309 

Preparation for improving the action of receptors


This preparation is advantageously applied in patients suffering from parkinson's disease, huntington's chorea, epilepsy, schizophrenia, paranoia, depression, sleep disorders, impaired memory function, psychoses, dementia and adhd.. .

01/29/15
20150031713 

Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators


Which are m1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the m1 receptor is involved, such as alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the m1 receptor..

01/15/15
20150018377 

Imidazolidinedione derivatives


The invention provides a compound of formula (ia), and pharmaceutically acceptable salts thereof. The invention also provides use of the compounds or salts as modulators of kv3.1 and/or kv3.2, and in the treatment of diseases or disorders where a modulator of kv3.1 and/or kv3.2 is required, such as depression and mood disorders, hearing disorders, schizophrenia, substance abuse disorders, sleep disorders or epilepsy..
Autifony Therapeutics Limited


01/08/15
20150007830 

Oral appliances and methods of use


Provided herein are oral appliances and methods of using oral appliances for treatment of sleep disorders and conditions.. .
Zst Holdings, Inc.


12/11/14
20140364395 

Pyranyl aryl methyl benzoquinolinone m1 receptor positive allosteric modulators


Which are m1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the m1 receptor is involved, such as alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the m1 receptor..

11/27/14
20140345060 

Systems, methods, and devices for the treatment of sleep disorders


A sleep apparatus, such as a mattress for example, is provided in one embodiment. The apparatus comprises a head support surface sized to support a person's head, and a torso support surface sized to support a person's torso.

11/20/14
20140343279 

Process for the preparation of histamine h3 receptor modulators


The present invention is directed to novel processes for the preparation of histamine h3 receptor modulators, in the treatment of for example, cognitive disorders, sleep disorders and/or psychiatric disorders.. .

11/13/14
20140336199 

Compounds and pharmaceutical compositions for treating disorders associated with the 5-ht1a and 5-ht2a receptors


Which are pharmacologicaly active and able to act on the 5-ht1a and 5-ht2a serotonin receptors in a manner that promotes the control, relief or cure of disorders associated with these receptors, and pharmaceutical compositions containing the compounds for the treatment of disorders associated with these receptors. These compounds and their pharmaceutical compositions are useful in the treatment of conditions such as depression, anxiety, phobias, addictions, aggressiveness, impulsiveness, panic, psychotic, eating and sleep disorders, obsessive-compulsive disorder and female sexual dysfunctions, among other disorders associated with these receptors..

10/30/14
20140323423 

Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders...


Systems and methods for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and treating hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, attention deficit disorder and nicotine addiction involve synchronizing and tailoring the administration of nutraceuticals, medications and other substances (for example, stimulants) in accordance with the body's natural circadian rhythms, meal times and other factors. Improved control of blood glucose levels, extended alertness, and weight control, and counteracting of disease symptoms when they are at their worst are possible.

10/16/14
20140309227 

Quinoline carboxamide and quinoline carbonitrile derivatives as mglur2-negative allosteric modulators, compositions, and their use


The present invention provides quinoline carboxamide and quinoline carbonitrile compounds of formula (i) wherein ring a, rq, -l-, r1, n, r2, and r3 are as defined herein. The compounds of the invention are useful as non-competitive mglur2 antagonists, or mglur2 negative allosteric modulators (nams), and in methods of treating a patient (preferably a human) for diseases or disorders in which the mglur2-nam receptor is involved, such as alzheimer's disease, cognitive impairment, schizophrenia and other mood disorders, pain disorders and sleep disorders, by administering to the patient a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof.

10/09/14
20140303372 

Sulfonylpyrazole and sulfonylpyrazoline carboxamidine derivatives as 5-ht6 antagonists


And derivatives thereof, which are antagonists of 5-ht6 receptors, wherein the symbols have the meanings given in the description. The invention also concerns methods for the preparation of these compounds, to novel intermediates useful for their synthesis, and to uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in treating at least on disease or condition chosen from parkinson's disease, huntington's chorea, schizophrenia, anxiety, depression, manic depression, psychoses, epilepsy, obsessive compulsive disorders, mood disorders, migraine, alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, binge eating disorders, panic attacks, akathisia, attention deficit hyperactivity disorder, attention deficit disorder, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, disorders associated with spinal trauma or head injury, hydrocephalus, functional bowel disorder, irritable bowel syndrome, obesity and type-2 diabetes..

10/09/14
20140303179 

Compounds and pharmaceutical compositions for treating disorders associated with the 5-ht1a and 5-ht2a receptors


This invention is related to the alkyl-piperazine-phenyl 4 (3h)-quinazolinones general formula (i) compounds, pharmacologicaly active and able to act on the 5-ht1a and 5-ht2a serotonin receptors in a manner that promotes the control, relief or cure of disorders associated with these receptors, and pharmaceutical compositions containing the compounds for the treatment of disorders associated with these receptors. These compounds and their pharmaceutical compositions are useful in the treatment of conditions such as depression, anxiety, phobias, addictions, aggressiveness, impulsiveness, panic, psychotic, eating and sleep disorders, obsessive-compulsive disorder and female sexual dysfunctions, among other disorders associated with these receptors..

09/04/14
20140249090 

Peptides and pharmaceutical compositions for use in the treatment by nasal administration of patients suffering from anxiety and sleep disorders


The present invention provides peptides for use in a medicament which is administered nasally, wherein the peptide is an agonist of neuropeptide s receptor (npsr), of the receptor tgr23 and/or of vasopressin receptor-related receptor 1 (vrr1) or for use in the treatment of a patient by causing, promoting or increasing relieve or healing of phobic anxiety, avoidance anxiety, dissociative anxiety such as flashbacks, depersonalization, derealization, intrusions, vegetative symptoms related to anxiety symptoms, especially in panic attacks, in posttraumatic stress disorder, in generalised anxiety disorder and in anxiety accompanying depressive, or psychotic episodes, arousal, awakening, alertness, activity, spontaneous movement, an anxiolytic effect or a combination thereof in the patient, wherein the peptide is administered nasally or for use in the prophylaxis and/or treatment of an anxiety or sleep disorder, especially in any type of hypersomnia like idiopathic hypersomnia, wherein the peptide is administered nasally. Further provided are pharmaceutical compositions for nasal administration comprising at least one of said peptides, uses of said peptide or said pharmaceutical composition.

08/14/14
20140228581 

Pde10 inhibitors and related compositions and methods


Compounds that inhibit pde10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as parkinson's disease, huntington's disease, alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, bell's palsy, cerebral palsy, sleep disorders, pain, tourette's syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. Pharmaceutically acceptable salts, stereoisomers, solvates and prodrugs of the compounds are also provided.

08/14/14
20140228562 

Treatment of sleep disorders


The use of 7-chloro-3-(5-dimethylaminomethyl-[1,2,4]oxadiazol-3-yl)-5methyl-4,5-dihydro-imidazol[1,5,-a][1,4]benzodiazepine-6-one or its pharmaceutically acceptable salt for treating various types of insomnia.. .

08/14/14
20140225736 

System and detecting sleep disorders


An apparatus for detecting sleep disorders, such as obstructive sleep apnea, includes a housing insertable into an ear canal of a subject. A sensor disposed within the housing measures a position of the subject's head relative to an axis of gravity.

08/07/14
20140221395 

Deuterium-enriched alkyl sulfonamides and uses thereof


The present invention is concerned with deuterium-enriched sulfonamides of formula 1, their pharmaceutically acceptable salts and methods of use thereof for the treatment of anxiety disorders including, general anxiety disorder (gad), panic disorder (pd), post-traumatic stress disorder (ptsd), social phobia (sp), health anxiety (hypochondriasis), depression, major depressive disorders, unipolar depression, bipolar i depression disorder, bipolar ii depression disorder, treatment-resistant depression, single episodic and recurrent major depressive disorders, depression in the medically ill, attention deficit hyperactivity disorder (adhd), attention deficit disorder (add), obsessive-compulsive disorder (ocd), obsessive-compulsive personality disorder (ocpd), autism spectrum disorder (asd), schizophrenia, psychosis, epilepsy, seizures, hot flashes due to menopause, age-related macular degeneration (amd), premature ejaculation, male erectile dysfunction, sexual dysfunction, obesity, eating disorders, bulimia nervosa, anorexia nervosa, angina, migraine, pain, nociception, sleep disorders, insomnia, fibromyalgia, alcohol withdrawal, autism, rett's syndrome, cyclothymic disorder, neural injury, neurodegenerative diseases, parkinson's disease, parkinson's disease psychosis, huntington disease, alzheimer's disease, frontotemporal dementia, cognitive impairment associated with age-related dementia, alzheimer's disease, schizophrenia, psychosis, depression, pain or discomfort associated with surgery and pain or discomfort associated with medical illness.. .

08/07/14
20140221322 

Heteroaryl substituted urea modulators of fatty acid amide hydrolase


Certain heteroaryl-substituted piperidinyl and piperazinyl urea compounds are described, which are useful as faah inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (faah) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, insulin resistance, diabetes, osteoporosis, and movement disorders (e.g., multiple sclerosis)..

07/24/14
20140207220 

Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolithic feed-through, lead assembly and anchoring mechanism


An implantable medical device is provided for the suppression or prevention of pain, movement disorders, epilepsy, cerebrovascular diseases, autoimmune diseases, sleep disorders, autonomic disorders, abnormal metabolic states, disorders of the muscular system, and neuropsychiatric disorders in a patient. The implantable medical device can be a neurostimulator configured to be implanted on or near a cranial nerve to treat headache or other neurological disorders.

07/17/14
20140200222 

N-linked quinolineamide m1 receptor positive allosteric modulators


The present invention is directed to n-linked quinoline amide compounds of general formula (i) which are m1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the m1 receptor is involved, such as alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the m1 receptor..

07/03/14
20140186457 

Honey composition with l-alanyl-l-glutamine


The present invention relates to compositions includes honey and l-alanyl-l-glutamine, pharmaceutical compositions thereof and a combined product comprising honey and l-alanyl-l-glutamine for a simultaneous, separate or sequential use in therapy. The composition, pharmaceutical composition and combined product have particular utility in improving sleep and treating sleep disorders such as insomnia or sleep apnoea..

06/19/14
20140171506 

Gamma-hydroxybutyrate compositions and their use for the treatment of disorders


Provided herein are pharmaceutical compositions and formulations comprising mixed salts of gamma-hydroxybutyrate (ghb). Also provided herein are methods of making the pharmaceutical compositions and formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus..

06/19/14
20140171505 

Gamma-hydroxybutyrate compositions and their use for the treatment of disorders


Provided herein are pharmaceutical compositions and formulations comprising mixed salts of gamma-hydroxybutyrate (ghb). Also provided herein are methods of making the pharmaceutical compositions and formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus..

05/29/14
20140148720 

Method and device(s) for diagnosis and/or treatment of sleep apnea and related disorders


Method and device for diagnosing and/or treating sleep apnea and related sleep disorders, such as snoring and respiratory effort-related arousals, includes an inflatable implement which is applied to the external surface of the chest and/or abdomen (vest). Pressure is caused to rise to a predetermined positive value.

05/29/14
20140148440 

Heterocyclyl compounds as histamine h3 receptor ligands


The present invention relates to heterocyclyl compounds of formula (i), and their pharmaceutically acceptable salts and compositions containing them. The present invention also relates to a process for the preparation of above said novel compounds, and their pharmaceutically acceptable salts.

04/17/14
20140107084 

Ultra low dose doxepin and methods of using the same to treat sleep disorders


The invention relates to doxepin, pharmaceutically acceptable salts and prodrugs of doxepin; compositions containing the same, and the use of any of the aforementioned for the treatment of sleep disorders.. .

03/06/14
20140066504 

Analogs and prodrugs of bumetanide; compositions and methods of use


Novel analogs and prodrugs of the loop diuretic bumetanide are described. Pharmaceutical compositions containing bumetanide analogs and prodrugs are also described.

03/06/14
20140066412 

Heteroaryl substituted urea modulators of fatty acid amide hydrolase


Certain heteroaryl-substituted piperidinyl and piperazinyl urea compounds are described, which are useful as faah inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (faah) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, insulin resistance, diabetes, osteoporosis, and movement disorders (e.g., multiple sclerosis)..

02/20/14
20140051750 

Low-dose doxepin for treatment of sleep disorders in elderly patients


Methods of treating sleep disorders, particularly certain aspects of insomnia, in elderly patients (65 years and older) by administering initial daily dosages of doxepin of 1-3 mg. These ultra-low initial dosages are more effective in elderly versus non-elderly patients in decreasing wake time during sleep, latency to persistent sleep and wake time after sleep, and are particularly efficacious in treating those conditions in the last hour of an 8-hour sleep cycle.

02/20/14
20140050783 

Methods and compositions for sleep disorders and other disorders


Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-ht2a, sert and/or dopamine d2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or parkinson's disease or any combinations..

02/13/14
20140045800 

Tetracyclic inhibitors of fatty acid amide hydrolase


Certain tetracyclic compounds are described, which may be used in pharmaceutical compositions and methods for treating disease states, disorders, and conditions mediated by fatty acid amide hydrolase (faah) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as multiple sclerosis)..

02/13/14
20140045755 

Methods for treating sleep disorders by cholecystokinin (cck) receptor b antagonists


The present invention relates to a method for preventing or ameliorating a sleep-related breathing disorder. The method involves the use of one or a combination of cholecystokinin (cck) receptor antagonists..

02/06/14
20140038951 

Pde10 inhibitors and related compositions and methods


Compounds that inhibit pde10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as parkinson's disease, huntington's disease, alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, bell's palsy, cerebral palsy, sleep disorders, pain, tourette's syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. Pharmaceutically acceptable salts, stereoisomers, solvates and prodrugs of the compounds are also provided.

01/09/14
20140011775 

Arylsulfonyl pyrazoline carboxamidine derivatives as 5-ht6 antagonists


This invention concerns arylsulfonyl pyrazoline carboxamidine derivatives as antagonists of 5-ht6 receptors, to methods for the preparation of these compounds and to novel intermediates useful for their synthesis. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in parkinson's disease, huntington's chorea, schizophrenia, anxiety, depression, manic depression, psychoses, epilepsy, obsessive compulsive disorders, mood disorders, migraine, alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, binge eating disorders, panic attacks, akathisia, attention deficit hyperactivity disorder, attention deficit disorder, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, disorders associated with spinal trauma or head injury, hydrocephalus, functional bowel disorder, irritable bowel syndrome, obesity and type-2 diabetes.

01/02/14
20140005182 

Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators


Which are m1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the m1 receptor is involved, such as alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the m1 receptor..

12/12/13
20130331610 

Halogenated pyrazolo[1,5-a]pyrimidines, processes, uses, compositions and intermediates


The invention provides novel halogenated pyrazolo[1,5-a]pyrimidines of formula (i) wherein r, r1, x and y have different meanings, and pharmaceutically acceptable salts thereof. Compounds of formula (i) are useful for treating or preventing anxiety, epilepsy and sleep disorders including insomnia, and for inducing sedation-hypnosis, anesthesia, sleep and muscle relaxation.

12/12/13
20130331571 

Glycine transporter-inhibiting substances


The compounds of the present invention are useful in the prevention or treatment of diseases such as schizophrenia, alzheimer's disease, cognitive impairment, dementia, anxiety disorders (e.g., generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, post-traumatic stress disorder, specific phobias, acute stress disorder), depression, drug dependence, spasm, tremor, pain, parkinson's disease, attention deficit hyperactivity disorder, bipolar disorder, eating disorder, or sleep disorders, which is based on the glycine uptake-inhibiting action.. .

12/12/13
20130331401 

Halogenated pyrazolo[1,5-a]pyrimidines, processes, uses, compositions and intermediates


The invention provides novel halogenated pyrazolo[1,5-a]pyrimidines of formula (i) wherein r, r1, x and y have different meanings, and pharmaceutically acceptable salts thereof. Compounds of formula (i) are useful for treating or preventing anxiety, epilepsy and sleep disorders including insomnia, and for inducing sedation-hypnosis, anesthesia, sleep and muscle relaxation.

12/12/13
20130331396 

Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase


Certain piperazinyl and piperidinyl urea compounds are useful as faah inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (faah) activity.

12/05/13
20130324788 

Method and treatment of sleep disorders


A system for therapy may include a mask (200) for a patient having a frame, cushion, forehead support and a light (100). The mask is connectable to a respiratory treatment apparatus, such as a flow generator, to receive breathable gas for a respiratory therapy.

11/28/13
20130312768 

Apparatus and methods for the treatment of sleep apnea


A medical apparatus for the treatment of one or more sleep disorders such as obstructive sleep apnea in a patient is provided. The apparatus comprises an elongate member with a middle portion, a first fixation element and a second fixation element.

11/07/13
20130296993 

Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolithic feed-through, lead assembly and anchoring mechanism


An implantable medical device is provided for the suppression or prevention of pain, movement disorders, epilepsy, cerebrovascular diseases, autoimmune diseases, sleep disorders, autonomic disorders, abnormal metabolic states, disorders of the muscular system, and neuropsychiatric disorders in a patient. The implantable medical device can be a neurostimulator configured to be implanted on or near a cranial nerve to treat headache or other neurological disorders.

11/07/13
20130296413 

N-desmethyl-doxepin and methods of using the same to treat sleep disorders


Desmethyldoxepin, isomers of desmethyldoxepin, and pharmaceutically acceptable salts and prodrugs of desmethyldoxepin; compositions containing the same, and the use of any of the aforementioned for the treatment of sleep disorders.. .

10/10/13
20130267595 

Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy


Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gamma-hydroxybutyrate that are also resistant to the conversion into gbl.

09/19/13
20130245022 

Heteroaryl-substituted urea modulators of fatty acid amide hydrolase


Certain heteroaryl-substituted piperidinyl and piperazinyl urea compounds are described, which are useful as faah inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (faah) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, insulin resistance, diabetes, osteoporosis, and movement disorders (e.g., multiple sclerosis)..

08/22/13
20130217729 

Piperidine sulphonamide derivatives


Wherein ar1, ar2, r1, r2, m and n are as defined in the description and claims, or pharmaceutically suitable acid addition salts thereof. The compounds of formula i are orexin receptor antagonists and the related compounds can be useful in the treatment of sleep apnea, narcolepsy, insomnia, parasomnia, jet lag syndrome, circadian rhythms disorder or sleep disorders associated with neurological diseases..

08/22/13
20130217700 

Pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto


Pyrazole derivatives of formula (ia) and pharmaceutical compositions thereof that modulate the activity of the serotonin 5ht2a receptor. Formula (ia).

08/15/13
20130210856 

Compositions and methods for treating sleep disorders


The present invention provides liquid dosage forms for treating narcolepsy. The liquid dosage form includes zolpidem or a pharmaceutically acceptable salt thereof, a carbonate salt, a metal oxide, and a borate salt.

08/01/13
20130196994 

Pde10 inhibitors and related compositions and methods


Compounds that inhibit pde10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as parkinson's disease, huntington's disease, alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, bell's palsy, cerebral palsy, sleep disorders, pain, tourette's syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. Pharmaceutically acceptable salts, stereoisomers, solvates and prodrugs of the compounds are also provided.

07/18/13
20130184298 

Dihydrobenzoquinazolinone m1 receptor positive allosteric modulators


The present invention is directed to dihydrobenzoquinazilinone compounds of formula (i) which are m1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the m1 receptor is involved, such as alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the m1 receptor..

07/18/13
20130184286 

Compounds and pharmaceutical compositions for treating disorders associated with the 5-ht1a and 5-ht2a receptors


This invention is related to the alkyl-piperazine-phenyl 4 (3h)-quinazolinones general formula (i) compounds, pharmacologically active and able to act on the 5-ht1a and 5-ht2a serotonin receptors in a manner that promotes the control, relief or cure of disorders associated with these receptors, and pharmaceutical compositions containing the compounds for the treatment of disorders associated with these receptors. These compounds and their pharmaceutical compositions are useful in the treatment of conditions such as depression, anxiety, phobias, addictions, aggressiveness, impulsiveness, panic, psychotic, eating and sleep disorders, obsessive-compulsive disorder and female sexual dysfunctions, among other disorders associated with these receptors..

06/13/13
20130150434 

Methods of using low-dose doxepin for the improvement of sleep


Methods of treating sleep disorders by administration of low doses of doxepin in individuals seeking sustained efficacy or in need of avoiding weight gain, rebound insomnia, or sedative tolerance resulting from doxepin treatment.. .

06/06/13
20130143965 

Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy


Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gamma-hydroxybutyrate that are also resistant to the conversion into gbl.

06/06/13
20130143912 

Sublingual zolpidem formulations


The present disclosure provides pharmaceutical compositions for the delivery of a hypnotic agent across the oral mucosa. In particular, the compositions devoid of buffer and in the presence of alkaline oxides capable of raising the ph of saliva to a ph greater than about 7.0 thereby facilitate the substantially complete conversion of the hypnotic agent from its ionized to its un-ionized form.

06/06/13
20130143868 

Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders


The present invention provides pharmaceutical compositions comprising droxidopa alone, or in combination with one or more further active ingredients, for the treatment of conditions, such as mood disorders, sleep disorders, or attention deficit disorders. In certain embodiments, the compositions useful in the methods of the invention comprise droxidopa and a compound selected from the group consisting of dopa decarboxylase inhibiting compounds, catechol-o-methyltransferase inhibiting compounds, cholinesterase inhibiting compounds, monoamine oxidase inhibiting compounds, norepinephrine reuptake inhibiting compounds, selective serotonin reuptake inhibiting compounds, tricyclic antidepressant compounds, serotonin norepinephrine reuptake inhibiting compounds, norepinephrine dopamine reuptake inhibiting compound, noradrenergic and specific serotonergic antidepressants, and combinations thereof.

05/30/13
20130137865 

Heteroaryl-pyrazole derivative


A compound represented by formula [i] and a pharmaceutically accepted salt of said compound are a novel compound and a pharmaceutically accepted salt thereof which exert antagonistic activity against group ii metabotropic glutamate (mglu) receptors, and are effective as a novel preventive or therapeutic agent for disorders such as mood disorders (depressive disorder, bipolar disorder, etc.), anxiety disorders (generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, posttraumatic stress disorder, a specific phobic disorder, acute stress disorder, etc.), schizophrenia, alzheimer's disease, cognitive impairment, dementia, drug dependence, convulsions, shivering, pain, sleep disorders, and the like.. .

05/16/13
20130123500 

Ethinyl-pyrazole derivative


Provided is a novel compound represented by formula [i] or a pharmaceutically acceptable salt thereof having antagonistic activity against group ii metabolism-type glutamic acid (m-glu) receptors. The compound or pharmaceutically acceptable salt thereof is useful as a prophylactic or therapeutic agent for diseases such as new mood disorders (depressive and bipolar disorders), anxiety disorders (generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, post-traumatic stress disorder, specific phobias, and acute stress disorder), schizophrenia, alzheimer's disease, cognitive dysfunction, dementia, drug dependence, convulsions, tremors, pain, sleep disorders, and the like..

05/16/13
20130122092 

Three-phase controlled-release tablet comprising melatonin and process of preparation


The invention relates, in one aspect, to a tablet having an internal core and external coating, both comprising melatonin and separated by an internal coating which does not comprise melatonin. The tablet is useful as a medicinal product, dietetic or food supplements for the treatment or as adjunctive therapy in sleep disorders..

05/16/13
20130118504 

System and delivering a therapy and sensing a biological activity in the mouth


Methods, devices, and systems are disclosed for controlled delivery of a therapy, such as a stimulant, to a mouth of a subject via an oral device positioned in a secured configuration in the mouth. At least one of a tongue position stimulator (tst) and tongue position sensor (tse) is provided, according to certain aspects.

05/09/13
20130116272 

Heterocyclic fused phenanthrolinone m1 receptor positive allosteric modulators


The present invention is directed to heterocyclic fused phenanthrolinone compounds of formula (i) which are m1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the m1 receptor is involved, such as alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the m1 receptor..

05/02/13
20130109686 

Isoindolone m1 receptor positive allosteric modulators


The present invention is directed to isoindolone compounds of formula (i) which are m1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the m1 receptor is involved, such as alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the m1 receptor..

04/25/13
20130102928 

System and managing sleep disorders


The present invention provides a method for managing a patient having a sleep disorder, e.g. Sleep apnea, snoring, sleep bruxism, upper airway resistance syndrome, etc.

04/25/13
20130102658 

Doxepin isomers and isomeric mixtures and methods of using the same to treat sleep disorders


The invention relates to use of the cis-(z) isomer or isomeric mixtures containing specified ratios of the cis-(z) and trans-(e) isomers of doxepin, metabolites of doxepin, pharmaceutically-acceptable salts of doxepin and prodrugs of the same; compositions containing the same, for the treatment of sleep disorders. .

04/25/13
20130102599 

Pyrazolo [4,3-c] cinnolin-3-one m1 receptor positive allosteric modulators


Which are m1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the m1 receptor is involved, such as alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the m1 receptor..

04/18/13
20130096188 

Doxepin trans isomers and isomeric mixtures and methods of using the same to treat sleep disorders


The invention relates to use of the trans-(e) isomer or isomeric mixtures containing specified ratios of the trans-(e) and cis-(z) isomers of doxepin, metabolites of doxepin, pharmaceutically-acceptable salts of doxepin and prodrugs of the same; compositions containing the same, for the treatment of sleep disorders. .

04/11/13
20130090352 

Tetrahydroquinoline amide m1 receptor positive allosteric modulators


The present invention is directed to tetrahydroquinoline amide compounds of formula (i) (formula should be inserted here) which are m1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the m1 receptor is involved, such as alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the m1 receptor..

03/28/13
20130078304 

Controlled release formulation for treating sleep disorders


The invention relates to a controlled-release formulation for preventing and/or treating sleep disorders comprising zaleplon or a pharmaceutically acceptable salt thereof in immediate release form and zolpidem or a pharmaceutically acceptable salt thereof in sustained release form, wherein zaleplon or a pharmaceutically acceptable salt thereof and zolpidem or a pharmaceutically acceptable salt thereof are released in two phases where the first phase is a immediate release phase of zaleplon or a pharmaceutically acceptable salt thereof and the second phase is a sustained release phase of zolpidem or a pharmaceutically acceptable salt thereof.. .

03/14/13
20130064804 

Bio-replenishment (biorep) for improving sleep architecture


Methods to prepare a bio-replenishment (biorep) with specific combinations of s-adenosylmethionine (same), lactoferrin (lf) and ribonuclease (rnase) to restore regular sleep pattern are described. Additionally, compositions of functional delivery systems that recreate both alternate phases of non-rapid eye movement (nrem) and rapid eye movement (rem) sleep cycles are disclosed.

03/07/13
20130059860 

Naphthalene carboxamide m1 receptor positive allosteric modulators


The present invention is directed to naphthalene carboxamide compounds of formula (i) which are m1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the m1 receptor is involved, such as alzheimers disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds and to the use of the compounds and compositions in the treatment of diseases mediated by the m1 receptor..

02/28/13
20130053398 

Modulators of fatty acid amide hydrolase


4-(2,2-difluoro-benzo[1,3]dioxol-5-ylmethyl)-piperazine-1-carboxylic acid (4-chloro-pyridin-3-yl)-amide is described, which is useful as a faah modulator. 4-(2,2-difluoro-benzo[1,3]dioxol-5-ylmethyl)-piperazine-1-carboxylic acid (4-chloro-pyridin-3-yl)-amide may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (faah) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy metabolism disorders, and movement disorders (e.g., multiple sclerosis).

02/21/13
20130042876 

System and delivering a therapy and sensing a biological activity in the mouth


Methods, devices, and systems are disclosed for controlled delivery of a therapy, such as a stimulant, to a mouth of a subject via an oral device positioned in a secured configuration in the mouth. At least one of a tongue position stimulator (tst) and tongue position sensor (tse) is provided, according to certain aspects.

02/14/13
20130040959 

Heterocyclic quinolizine derived m1 receptor positive allosteric modulators


The present invention is directed to novel 3-oxo-2,3-dihydropyrazolo[4,3-c]quinolizine derived compounds of generic formula (i) or a pharmaceutically acceptable salt thereof, which are m1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the m1 receptor is involved, such as alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the m1 receptor..

01/31/13
20130029291 

Dual use exercise whitener appliance


A jaw-joint protective device is provided for whitening and brightening a wearer's teeth while protecting the teeth, tongue, lips, jaw, and other delicate structures of the vital cranial triad (vct) from injury and/or for supporting the condyle of the temporomandibular joint (tmj) in a relatively fixed (stable) position thereby stabilizing the jaw and the vct during head contact activity, exercise, physical rehabilitation, c-force acceleration, teeth grinding disorders and sleep apnea and or permit the components of a vct disorder to be realigned for proper healing. This device is an over-the-counter purchased, boil and bite device for whitening at least one tooth while protecting the jaw-joint, providing maxillary and mandibular teeth seats for protection of the mouth and/or healing of the vct.

01/24/13
20130021158 

System and detecting sleep disorders


An apparatus for detecting sleep disorders, such as obstructive sleep apnea, includes a housing insertable into an ear canal of a subject. A sensor disposed within the housing measures a position of the subject's head relative to an axis of gravity.

01/17/13
20130018090 

Low-dose doxepin for treatment of sleep disorders in elderly patients


Methods of treating sleep disorders, particularly certain aspects of insomnia, in elderly patients (65 years and older) by administering initial daily dosages of doxepin of 1-3 mg. These ultra-low initial dosages are more effective in elderly versus non-elderly patients in decreasing wake time during sleep, latency to persistent sleep and wake time after sleep, and are particularly efficacious in treating those conditions in the last hour of an 8-hour sleep cycle.



Popular terms: [SEARCH]

Sleep Disorders topics: Sleep Disorder, Sleep Disorders, Narcolepsy, Schizophrenia, Antagonist, Pyrazole Derivatives, Movement Disorder, Movement Disorders, Eating Disorder, Eating Disorders, Neurological, Pharmaceutically Acceptable Salt, Intracranial, Opiate Withdrawal, Growth Hormone

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Sleep Disorders for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Sleep Disorders with additional patents listed. Browse our RSS directory or Search for other possible listings.


1.011

4638

1 - 1 - 91